Skip to search.

Breaking News Visit Yahoo! News for the latest.

×Close this window

 Dow Up0.06% Nasdaq Down0.01%

Merrimack Pharmaceuticals, Inc. (MACK)

-NasdaqGM

5.20 Down 0.06(1.14%) 4:00PM EDT|After Hours : 5.20 Up 0.00 (0.02%) 4:36PM EDT

Add to Portfolio
Income StatementGet Income Statement for:
View: Annual Data | Quarterly DataAll numbers in thousands
Period EndingMar 30, 2013Dec 30, 2012Sep 29, 2012Jun 29, 2012
Total Revenue 14,655   14,191   11,323   12,063  
Cost of Revenue -   -   -   -  
Gross Profit 14,655   14,191   11,323   12,063  
Operating Expenses
Research Development36,989  34,564  30,885  28,758  
Selling General and Administrative4,932  4,155  4,312  3,610  
Non Recurring -   -   -   -  
Others -   -   -   -  
Total Operating Expenses -   -   -   -  
Operating Income or Loss (27,266) (24,528) (23,874) (20,305)
Income from Continuing Operations
Total Other Income/Expenses Net163  188  554  165  
Earnings Before Interest And Taxes(27,103)(24,340)(23,320)(20,140)
Interest Expense1,220  553   -  (1)
Income Before Tax(28,323)(24,893)(23,320)(20,139)
Income Tax Expense -   -   -   -  
Minority Interest170  125  121  113  
Net Income From Continuing Ops(28,153)(24,768)(23,199)(20,026)
Non-recurring Events
Discontinued Operations -   -   -   -  
Extraordinary Items -   -   -   -  
Effect Of Accounting Changes -   -   -   -  
Other Items -   -   -   -  
Net Income (28,153) (24,768) (23,199) (20,026)
Preferred Stock And Other Adjustments -   -   -   -  
Net Income Applicable To Common Shares (28,153) (24,768) (23,199) (20,026)

Sign Up for a Free Trial to EDGAR Online Premium!
Get the critical business and financial information you need for more than 15,000 U.S. public companies.
Sign Up Now - Learn More

Currency in USD.